Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
GTC Bio

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 29 November 2002:
Vol. 298. no. 5599, pp. 1704 - 1705
DOI: 10.1126/science.298.5599.1704
Prev | Table of Contents | Next

News Focus

REGULATORY RESEARCH:
A Centennial Letdown for FDA's Biologics Group

Bruce Agnew

New leaders at the Food and Drug Administration are pushing a big shakeup of the division that oversees biologics in a way that seems to de-emphasize research, although they cite other reasons for making changes. However, many researchers at the Center for Biologics Evaluation and Research and outside scientists have begun arguing that the real purpose of the move is to strip away CBER's special status as a regulator that also supports substantial intramural research.

Read the Full Text

ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)